# Vision X

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vision-x

- Industry: Medical Devices & Equipment
- Headquarters: Zhuhai, China
- Total disclosed funding: $114M
- Latest round: Series B (Sep 30, 2021)
- Investors on record: 10

## About

Established in 2019 and based in Zhuhai, China, Vision X is a medical technology company that engaged in ophthalmic medical device development and production, providing eye care products and eye optometry equipment. In September 2021, the company raised more than USD 100 million in serjes B funding.

The company's business covers juvenile myopia prevention and control, adult vision correction and ocular surface disease treatment, optometry diagnosis and treatment equipment, nursing products and other consumer products. The company's RGP product of rigid corneal contact lens "Aikangfei" has been put on the market in 2021.

## Funding rounds

- Series B, Sep 30, 2021, $100M — Hong Shan, Temasek Holdings, Green Pine Capital Partners, HighLight Capital, Sherpa Healthcare Partners, 3H Health Investment, Lake Bleu Capital
- Series A, Aug 12, 2020, $14M — Hong Shan, Green Pine Capital Partners, YuanBio Venture, Fosun Capital, Hengqin Financial Investment, Sherpa Healthcare Partners

## Investors

- Hong Shan — Series A, Series B
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series A, Series B
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Fosun Capital (https://capitalatlas.ai/funds/fosun-capital) — Series A
- Hengqin Financial Investment (https://capitalatlas.ai/funds/hengqin-financial-investment) — Series A
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A, Series B
- Temasek Holdings — Series B
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- 3H Health Investment (https://capitalatlas.ai/funds/3h-health-investment) — Series B
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series B